Kornimate/medical-research-clean huggingface dataset:
role of inflammation in carpal tunnel syndrome

Conditions: Carpal Tunnel Syndrome; Median Neuropathy, Carpal Tunnel

Summary: this study aims to investigate the role of inflammation in carpal tunnel syndrome (cts) using a prospective cohort study design. the study will involve a sample of at least 50 individuals with cts who will undergo a comprehensive clinical and biochemical evaluation to assess the role of inflammation in cts. the primary outcome measures include inflammatory markers, such as c-reactive protein (crp), interleukin-6 (il-6), and tumor necrosis factor-alpha (tnf-α), as well as clinical measures of cts severity. data will be analyzed using regression analysis to determine the relationship between inflammation and cts. the study is expected to provide information on the role of inflammation in cts and inform the choice of drug and concentration for transdermal drug administration.


Eligibility criteria:
inclusion criteria: * individuals aged 18 years or older * diagnosis of carpal tunnel syndrome based on clinical symptoms and nerve conduction studies * willingness and ability to provide informed consent to participate in the study * willingness and ability to comply with study procedures and follow-up visits exclusion criteria: * presence of other neurological conditions that may affect nerve function in the upper extremities * use of medications that may affect inflammation or carpal tunnel syndrome severity * history of previous carpal tunnel release surgery on the affected wrist * inability to comply with study procedures or follow-up visits * pregnancy or breastfeeding
the effect of celecoxib on the antiplatelet effect of aspirin and clopidogrel in normal volunteers

Conditions: Healthy

Summary: background: * the prevalence of arthritis which needs celecoxib prescription is high in patients with coronary artery disease. * the main concern is that celecoxib would increase thrombogenicity by inhibiting the synthesis of prostacyclin in endothelial cells. * it is not known whether the administration of celecoxib would deteriorate antiplatelet effects of aspirin and clopidogrel which are used after stenting. methods: * healthy volunteers (n=40) * randomization into five subgroups * aspirin, celecoxib, aspirin+celecoxib, aspirin+clopidogrel, aspirin+clopidogrel+celecoxib * medication schedule : medication of each drug for 6 days, blood samples at day 0 and day 7 * celecoxib 200mg twice a day, and/or aspirin 100mg daily, and/or clopidogrel 75 mg daily * platelet function test : light transmittance aggregometry and arachidonic acid metabolite assay among subgroups. study hypothesis : the addition of celecoxib does not deteriorate antiplatelet function of aspirin and clopidogrel.


Eligibility criteria:
inclusion criteria: * healthy volunteers including both men and women 20\~30 years * no abnormality in physical examination, 12-lead ecg, and routine laboratory test exclusion criteria: * subjects with cardiovascular disease, hemostatic disorder, hypersensitivity to nsaids and clopidogrel * women with a positive pregnancy test * smoker * chronic drinkers * overweight exceeding 20% of standard body weight

Keywords: celecoxib platelet thrombosis volunteers
cpap effect on vascular function in obstructive sleep apnea

Conditions: Obstructive Sleep Apnea

Summary: obstructive sleep apnea syndrome is responsible of endothelial dysfunction, which is a independent cardio-vascular risk factor. assessment of pulse wave velocity (pwv) and peripheral arterial tone (pat) are study measurements of arterial stiffness, and are strong predictors of late cardiovascular events. this study will compare long term evolution in arterial stiffness (pwv) and endothelial dysfunction (pat) for patients treated by positive airway pressure therapies.

obstructive sleep apnea (osa) syndrome is responsible of vascular damage. intermittent hypoxia causes oxidative stress and low-grade inflammation. by the way of increased sympathetic outflow, it's resulting endothelial dysfunction, atherosclerosis and an increase of arterial stiffness. finally these mechanisms are responsible of cardiovascular comorbidities: hypertension, cardiac arrhythmias or left ventricular dysfunction. this patients presented coronary diseases or strokes. osa characterized by intermittent hypoxia, is associated with atherosclerosis and vascular inflammation. polymorphonuclear leukocytes (pmns) are implicated in vascular inflammation by producing oxidizing radicals and proteolytic enzymes during pmn-endothelium interactions. reactive oxygen species (ros) production is increased in activated cells and after attachment, pmns release additional ros inducing endothelial cell injury. continuous positive airway pressure (cpap) is the current "gold standard" treatment for osa, use of cpap restored the respiratory flow, prevents nocturnal respiratory events and daytime symptoms. arterial stiffness and endothelial dysfunction are linked to obstructive sleep apnea severity with a dose-effect relationship. and meta-analyse showed significant improvements in all indices of arterial stiffness after cpap treatment in patients with osa. assessment of pulse wave velocity and peripheral arterial tone are study measurements of arterial stiffness. and are strong predictors of late cardiovascular events the investigators will compare long term evolution in arterial stiffness (pwv) and endothelial dysfunction (peripheral arterial tone) for patients with osa treated by positive airway pressure therapies.

Eligibility criteria:
inclusion criteria: * any patient with a initial visit there is 4-7 years for the vni-soh protocol (réf cpp sud-est v: 38/2006/2) * male or female patient, aged 20-75 years at the initial visit there is 4 to 7 years; * patients with a bmi\> 30kg / m2 at diagnostic; * patient affiliated to a social security; * having given its written consent to participate in the study. exclusion criteria: * person private of liberty by judicial or administrative decision, person under legal protection measure (pregnant or nursing, patient under guardianship) article l1121-8 * exclusion period for further studies * patient died or lost sight since the initial visit there 4-7 years

Keywords: obstructive sleep apnea endothelial dysfunction arterial stiffness pap therapies
feasibility of biodynamic imaging for predicting therapeutic effect in metastatic adenocarcinoma of the pancreas

Conditions: Metastatic Pancreatic Cancer

Summary: the purpose of this study is to determine if you can use an assay on tumor samples to see different patterns in response to the same chemotherapy treatment.

to examine the feasibility of using biodynamic imaging (bdi) as a chemosensitivity assay on fresh tumor samples obtained by core needle biopsy from patients planned to receive routine care gemcitabine and nab-paclitaxel for treatment of metastatic adenocarcinoma of the pancreas.

Eligibility criteria:
inclusion criteria: 1. ability to understand and willingness to sign an informed consent and authorization for release of health information for research 2. ≥ 18 years old at time of consent 3. patients with a diagnosis of metastatic pancreatic cancer (mpc) who have not received prior combination chemotherapy. exception: prior adjuvant chemoradiation with fluorouracil or gemcitabine is allowed. 4. patients considered for routine care treatment with gemcitabine and nab-paclitaxel (allowed to receive other experimental therapy with gem/nab backbone if participating in another clinical trial) 5. measurable disease by recist v1.1 criteria 6. eastern cooperative oncology group (ecog) performance status (ps) of 0-1 7. willingness to undergo transcutaneous core needle biopsy of metastatic tumor for research purposes 8. women are eligible to participate if they are of non-childbearing potential or have documentation of a negative pregnancy test (serum or urine β-hcg) within 1 week of the start of protocol treatment. 9. women and men of childbearing potential must agree to use adequate, highly effective contraceptive measures during protocol treatment 10. laboratory values: platelets ≥ 100 k/mm3 international normalized ratio (inr) \< 1.2, partial thromboplastin time (ptt) in normal range, cr \< 2.0, total bilirubin \< 2 times upper limit normal (uln), transaminases \< 5 times uln exclusion criteria: 1. history of abnormal bleeding with minor procedures or documented platelet aggregation disorder such as vonwillebrand disease 2. women who are pregnant or breastfeeding
the roles of hilotherapy in the management of epistaxis and nasal fractures

Conditions: Epistaxis

Summary: the investigators aimed to assess primarily whether or not hilotherapy masks are a tolerable treatment for the conservative management of epistaxis and nasal fractures.

participants who had ongoing epistaxis and met the inclusion criteria where enrolled in the pilot study . bleeding severity was not recorded. all participants enrolled were clinically stable with active epistaxis. participants who were unstable or were ineligible were not referred to the recruiting doctors by a\&e triage. following informed consent the hilotherm mask was fitted for an initial period of 20 minutes. if the bleeding had improved or stopped following 20 minutes of treatment the hilotherm mask remained fitted for a 20 further minutes . a subjective decision was made by the supervising doctor and the participant to whether the flow of epistaxis had improved after the initial 20 minutes of hilotherapy. the mask was removed if there was no improvement after the initial 20 minutes of hilotherapy, 40 minutes of total hilotherapy treatment, participant preference, worsening observations or profuse bleeding. participants received conventional epistaxis management simultaneously, this involved continued nasal pressure application during hilotherapy. following hilotherapy if epistaxis continued then either nasal cauterisation or packing was performed. participants who were packed cessation of epistaxis was determined at the time of packing if bleeding had ceased. bleeding time was accurately assessed by the recruiting doctor from the time of hilotherm mask application to the time of complete epistaxis cessation. all of the participants were treated in the sitting position. participants were free to withdraw from the trial at any time and no further data was analysed from the individual. clinicians recorded anticoagulant and antiplatelet use, duration of bleeding and patient demographics. all participants completed a questionnaire following their hilotherapy treatment independantly. a similar protocol was devised for nasal fractures.

Eligibility criteria:
inclusion criteria: * presenting to ed with epistaxis or nasal fractures ( over 18 years) exclusion criteria: * laceration around site of mask, reduced gcs, concurrent head injury, systemic shock
red cell rejuvenation for the attenuation of transfusion associated organ injury in cardiac surgery

Conditions: Organ Failure, Multiple; Inflammation; Sepsis

Summary: the redjuvenate trial proposes to test the hypothesis that postoperative organ injury and inflammation will be less if patients undergoing cardiac surgery who are at risk of large volume blood transfusion (defined as the administration of ≥4 units of red cells) receive rejuvenated washed cells compared to standard care (unwashed aged stored cells).

in the redjuvenate trial, we propose to establish whether the administration of rejuvenated red cells will reduce inflammation and organ injury in cardiac surgery patients at risk of large volume blood transfusion when compared to standard care. organ injury and sepsis accounts for the majority of all deaths following cardiac surgery. once organ injury is established care is primarily supportive and there are no effective treatments. prevention is therefore a key clinical strategy to prevent death, morbidity and high healthcare costs attributable to these complications. sepsis and inflammatory organ injury are also the principal causes of death following paediatric cardiac surgery, trauma, non-cardiac complex surgical procedures and in critical care; clinical settings that are also among the principal consumers of blood components. national and international blood management strategies are focused on these patients. evidence of a clinical benefit attributable to the use of rejuvenated red cells in cardiac surgery patients is therefore likely to translate into more widespread benefits to patients and the national health service (nhs).

Eligibility criteria:
inclusion criteria: 1. adult cardiac surgery patients (≥18 years) undergoing cardiac surgery with cardiopulmonary bypass. 2. identified as representing a high risk group for massive blood transfusion using a modified risk score. a large volume blood transfusion (lvbt) score of \>23 indicates predicted risk of receiving ≥4 units of allogeneic red cells equal to or greater than 55 per cent. exclusion criteria: 1. emergency or salvage procedure 2. patients with end stage renal failure defined as an estimated glomerular filtration rate (egfr) \<15 ml/min/1.72 m2 calculated from the modification of diet in renal disease equation, or patients who are on long-term haemodialysis or have undergone renal transplantation. 3. patients who are prevented from having blood and blood products according to a system of beliefs (e.g. jehovah's witnesses). 4. patients with a pre-existing sepsis or organ injury defined as documented sepsis, acute kidney injury, acute lung injury, myocardial infarction, low cardiac output, liver injury, stroke or pancreatitis within 5 days of surgery. 5. pregnancy. 6. patients who are participating in another interventional clinical study. 7. patients requiring irradiated blood. 8. sickle cell anaemia.
wbv and serial casting for children with cerebral palsy

Conditions: Cerebral Palsy (CP); Cerebral Palsy

Summary: children with cerebral palsy have increased muscle tone which often results in decreased active and passive movement at the ankle. while many management strategies exist (including passive stretching, wbv, serial casting, botox, and surgical tendon lengthening), the utilization of wbv in combination with active exercises and serial casting has not been previously explored. serial casting is the repeated application of a fiberglass cast (such as that applied to manage stable fractures) on a scheduled (usually weekly basis) to gradually increase the range of motion at a specific joint. it is theorized that combining previously established standard of care practices may result in more rapid clinical change, and hence reduce the need for prolonged intervention; ultimately reducing healthcare costs.


Eligibility criteria:
inclusion criteria: * ages 3-17 and 32 weeks exclusive years; * diagnosis of cerebral palsy; * gmfcs levels i-iii; * stands with upper extremity support or less support; * active referral from a prescribing provider for serial casting with ankle df of \<10 degrees; * willing to pursue care at \[primary site\] outpatient physical therapy clinic for the duration of the study; * subjects/families must be able to communicate in the english language without the need for interpreter. exclusion criteria: * history of selective dorsal rhizotomy; * previous achilles tendon lengthening or other orthopedic interventions to the lower extremities in 1 year prior to enrollment; * no botox or changes in oral medication to reduce spasticity within 6 months prior to enrollment; * skin, circulation, vascular conditions; * previous history of cancer; * reduced ankle/foot sensation; * allergies to casting materials.

Keywords: serial casting whole body vibration cerebral palsy pediatrics
radiation therapy after surgery in treating women with early stage breast cancer

Conditions: Breast Cancer

Summary: rationale: radiation therapy uses high-energy x-rays to damage tumor cells. it is not yet known which regimen of radiation therapy is more effective following surgery for breast cancer. purpose: randomized phase iii trial to compare the effectiveness of two different regimens of radiation therapy following surgery in treating women who have early stage breast cancer.

objectives: * determine the benefits of radiotherapy schedules using fraction sizes larger than 2.0 gy in terms of normal tissue responses, local-regional tumor control, quality of life, and economic consequences in women prescribed postoperative radiotherapy for early stage breast cancer. outline: this is a randomized, multicenter study. patients are stratified according to center, type of surgery (mastectomy vs local excision), and breast boost (yes vs no). patients are randomized to 1 of 3 treatment arms. * arm i: patients receive radiotherapy 5 times a week for 5 weeks for a total dose of 50 gy. * arm ii: patients receive radiotherapy 5 times a fortnight (i.e., monday/wednesday/friday/tuesday/thursday/monday, etc.) for 13 fractions over 5 weeks for a total dose of 41.6 gy. * arm iii: patients receive radiotherapy as in arm ii for a total dose of 39 gy. a breast boost is recommended in all arms for patients with microscopic evidence of invasive or in situ cancer at, or within 1 mm of, a resection margin. these patients receive radiotherapy for 5 fractions in 1 week for a total boost dose of 10 gy. quality of life is assessed at baseline and then at 6, 12, 24, and 60 months. patients are followed annually for up to 20 years. projected accrual: a total of 2,010 patients (670 per arm) will be accrued for this study.

Eligibility criteria:
disease characteristics: * histologically confirmed invasive unilateral breast cancer that is considered operable * t1-3, n0-1, m0 at presentation * complete macroscopic excision of tumor by breast conserving surgery or mastectomy * no immediate breast reconstruction * no requirement for axillary radiotherapy after greater than a level 1 axillary dissection or after greater than 10 lymph nodes have been removed * not enrolled on secrab or oscar trials * hormone receptor status: * not specified patient characteristics: age: * 18 and over sex: * female menopausal status: * not specified performance status: * not specified life expectancy: * not specified hematopoietic: * not specified hepatic: * not specified renal: * not specified prior concurrent therapy: * prior neoadjuvant, or primary medical, therapy allowed provided subsequent surgery confirms complete macroscopic excision of residual primary tumor biologic therapy: * not specified chemotherapy: * at least 2 weeks since prior cytotoxic agents * no concurrent chemotherapy endocrine therapy: * not specified radiotherapy: * see disease characteristics surgery: * see disease characteristics

Keywords: stage i breast cancer stage ii breast cancer stage iiia breast cancer
clinical study of ak1820 (isavuconazonium sulfate) for the treatment of deep mycosis

Conditions: Deep Mycosis

Summary: the objective of this study is to investigate the safety and efficacy of administering 372.6 mg of ak1820 (isavuconazonium sulfate) intravenously or orally to adult japanese patients with deep mycosis. the primary endpoint is safety (percentage of patients with adverse events after starting the study treatment).


Eligibility criteria:
main inclusion criteria: * patients must have the below proven, probable or possible deep mycosis; 1. invasive aspergillosis 2. chronic pulmonary aspergillosis 3. mucormycosis 4. cryptococcosis * female patients must be non-lactating and at no risk for pregnancy. main exclusion criteria: * women who are pregnant or breastfeeding. * patients with hypersensitivity to any of the components of the azole class of antifungals or the investigational product. * patients at high risk for qt/qtc prolongation, or patients with risk factors for torsades de pointes, or taking concomitant medications known to prolong the qt/qtc interval. * patients with a history of short qt syndrome. * patients with liver dysfunction at enrollment. * patients with moderate to severe kidney dysfunction at enrollment. * patients who receive prohibited concomitant drugs. * patients with any other fungal infection other than aspergillus species, order mucorales, or cryptococcus species. * patients who are not expected to survive study duration. * patients with an underlying disease, complication or general condition that would complicate safety and efficacy evaluations. * patients with a history of taking voriconazole for deep mycosis and showing no response to this treatment. * patients taking systemic antifungals who are unable to stop taking these drugs during the study, or who are showing signs of improvement in their symptoms of deep mycosis as a result of these drugs.

Keywords: deep mycosis aspergillosis mucormycosis cryptococcosis isavuconazonium sulfate isavuconazole ak1820 cresemba
study of the endovascular quantum lp™ stent graft system in abdominal aortic aneurysms (aaa)

Conditions: Abdominal Aortic Aneurysm

Summary: the objective of this clinical study is to assess the safety and effectiveness of the cordis endovascular quantum lp™ stent graft system.


Eligibility criteria:
inclusion criteria (surgical patients): 1. non-emergent surgical candidate (aneurysm has not ruptured) 2. patients 21 years of age or older 3. male or infertile female 4. aneurysm \>/=4.5 cm in diameter, or 5. aneurysm \>/= twice the normal aortic diameter directly above the aneurysm, or 6. aneurysm \>/= 4.0 cm in diameter and rapidly growing (0.5 cm in 6 months), or 7. saccular aneurysm \> 3.0 cm inclusion criteria (stent graft patients) 1. patient meets all inclusion criteria for surgical candidate 2. aneurysm starts \>/= 10 mm below the most distal main renal artery and the diameter of aorta within that aortic neck segment is not variable 3. diameter of aortic fixation zone (neck) \>/= 22mm and \</= 30 mm 4. supra renal aortic diameter \</= 34 mm 5. the required device coverage length \>/= 13 cm extending from most distal main renal artery ostium to the distal anchoring site within the common iliac artery (or external iliac artery if planned occlusion of internal iliac artery) 6. aortic neck angulation \< 60° as estimated from ct scan images or angiogram 7. iliac artery attachment zone diameter \</= 20 mm 8. iliac arteries with a length of \>/= 10 mm of non-aneurysmal vessel located at the iliac graft attachment sites 9. iliac arteries with adequate peripheral access to accommodate a 22 fr catheter delivery system 10. aortic bifurcation \> 18 mm in diameter 11. creatinine level \< 2.5 mg/dl exclusion criteria (surgical and stent graft patients): 1. weight \> 350 lbs. (159 kg) 2. mycotic, ruptured or traumatic aneurysm 3. life expectancy \< 2 years 4. mi, cerebral vascular accident or transient ischemic attack (tia) within 6 months 5. expected occlusion or the need for re-implantation of significant mesenteric or renal arteries originating from the aaa exclusion criteria (stent graft patients only) 1. aneurysm is symptomatic or tender 2. creatinine \> 2.5 mg/dl or patient on dialysis 3. thrombus in proximal and distal attachment area covering greater than 50% of the endoluminal surface